Description
This study involves taking the study drug, abatacept, by intravenous (IV) infusion. Along with the study drug, participants will take a either cyclosporine or tacrolimus, and methotrexate, which are standard medications for transplant patients. Participants, 6 years of age and older, will be randomized (placed into a group by chance) by the study team. After being placed into a group, you will receive additional doses of either abatacept (the study drug) or a placebo (an inactive substance).
What to expect
If you agree to take part, your participation will last for about 2 years post-transplant. You will receive study treatment for 150 days post-transplant. There are differences between this study and your usual care. As a participant in the research, you will be given abatacept (or placebo) by IV infusion. Study visits will include the following assessments: blood draws, pregnancy testing/birth control, genetic testing, and tissue collections (for clinical and research purposes). Some of these assessments are only if you are 18 years or older. All participation will occur at CHOPâs main campus in Philadelphia.Â
